Does that child really have an antibiotic allergy?

Publication
Article
Contemporary PEDS JournalJune 2022
Volume 40
Issue 5

Most children outgrow an adverse drug reaction to oral antibiotics, according to an Icelandic study.

Most children outgrow an adverse drug reaction to oral antibiotics, according to a retrospective observational study conducted in Iceland.

One to 2 years after an antibiotic provocation test was conducted in 1440 participants aged 5 months to 18 years, investigators conducted a second provocation test in 64 of the 92 participants who showed a possible mild allergic reaction after the first test. Participants received one-tenth of a full standard dose of the same antibiotic they originally received, most often amoxicillin with or without clavulanic acid (85.7%). Late mild reactions, mostly rashes, were seen in 11 participants, and 53 had no reaction at all. Investigators concluded that it is safe to perform an oral antibiotic provocation test after a mild possible allergic reaction and that patients who have a mild reaction to antibiotics at one time may possibly be prescribed the same antibiotic later.

Thoughts from Dr Farber

Too many children and adolescents have received an erroneous diagnosis of antibiotic allergy, resulting in the use of less optimal or more expensive medicine. This study indicates that mild

confirmed allergies can be outgrown,

and a pediatrician, if comfortable doing

so, can conduct an oral challenge in the

office in these patients.

Reference:

Gu›nadóttir GK, Jónasson G, Clausen M, Sørensen TG, Kristjánsson S. Antibiotic oral provocation challenge in children. Acta Paediatr. 2022;111(5):1056-1060. doi:10.1111/apa.16211

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jillian Cotter, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.